Probenecid (PB) to Treat Hereditary Nephrogenic Diabetes Insipidus (NDI), ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration

NCT05190744 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Autosomal Dominant Polycystic Kidney Disease
Nephrogenic Diabetes Insipidus
Acquired Nephrogenic Diabetes Insipidus
Congenital Nephrogenic Diabetes Insipidus

Interventions

DRUG: PB

Sponsor

Mayo Clinic

Collaborators

[object Object]